Pre-Tax Profit Margin (Quarterly)

Pre-Tax Profit Margin: Earnings before taxes as a portion of total revenue. Calculated as: Pre-Tax Income / Total Revenues

Esperion Therapeutics, Inc. (ESPR) had Pre-Tax Profit Margin of -31.45% for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$80.10M
Net Income	$-25.20M
Cost of Goods Sold	$34.57M
Gross Profit	$45.53M
Operating Expenses	$86.69M
Operating Income	$-6.58M
Non-Operating Income/Expense	$-18.61M
Pre-Tax Income	$-25.20M
Normalized Pre-Tax Income	$-25.20M
Income after Taxes	$-25.20M
Income from Continuous Operations	$-25.20M
Consolidated Net Income/Loss	$-25.20M
Normalized Income after Taxes	$-25.20M
EBIT	$-6.58M
EBITDA	$-5.96M
Weighted-Average Shares Outstanding (Basic)	251.35M
Weighted-Average Shares Outstanding (Diluted)	251.35M
Earnings per Share (EPS) (Basic)	$-0.10
Earnings per Share (EPS) (Diluted)	$-0.10
Balance Sheet Financials
Current Assets	$459.46M
Property, Plant, and Equipment	$0.31M
Long-Term Assets	$3.07M
Total Assets	$462.53M
Current Liabilities	$300.36M
Long-Term Debt	$250.07M
Long-Term Liabilities	$470.10M
Total Liabilities	$770.46M
Common Equity	$-307.93M
Tangible Shareholders Equity	$-307.99M
Shareholders Equity	$-307.93M
Common Shares Outstanding	257.40M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-27.72M
Cash Flow from Investing Activities	$-0.19M
Cash Flow from Financial Activities	$16.22M
Beginning Cash	$167.85M
End Cash	$156.16M
Increase/Decrease in Cash	$-11.69M
Stock-Based Compensation	$2.50M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.53
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-4.32
Debt to Equity Ratio	-0.81
Gross Margin	56.84%
Operating Margin	-8.22%
EBIT Margin	-8.22%
EBITDA Margin	--
Pre-Tax Profit Margin	-31.45%
Profit Margin	-31.45%
Free Cash Flow	$-27.91M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.17
Inventory Turnover	0.33
Receiveable Turnover	0.61
Days Sales in Receivables	148.70
Return on Equity	8.18%
Return on Tangible Equity	8.18%
Return on Assets	-5.45%
Return on Investments	43.54%
Book Value Per Share	$-1.20
Free Cash Flow per Share	$-0.11
Operating Cash Flow per Share	$-0.11

Data from Zacks Investment Research, Inc.